Some patients want to take a holiday pause on weight-loss drugs. Here's what doctors say
The effects that a pause may have on your body may depend on why you're taking the medication in the first place.
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
24/7 Wall St3h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
Coffee, tea may offer protection from some cancers, study indicates
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and ...
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Medscape7h
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
WRAL7h
Some patients want to take a holiday pause on diabetes or weight-loss drugs. Here’s what doctors say they need to know
Different risks for different people GLP-1 receptor agonists and dual agonists – such as Ozempic, Wegovy, Mounjaro and Zepbound – are typically used as weekly injections. The GLP-1 receptor agonists ...
We've Accepted Wegovy and Zepbound. The Next Phase Is Harder.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
McKnight's Long-Term Care News10h
FDA says shortage of GLP-1 tirzepatide is over
The US Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.
Zepbound and Mounjaro are the two best-in-class products right now, says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the future of pharmaceutical advertising, health ...
dailymemphian18h
‘It’s bonkers’ — how Ozempic, Wegovy change lives of those who struggle to lose weight
Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...